BRGX — BioRegenx Income Statement
0.000.00%
Last trade - 00:00- $15.02m
- $17.13m
- $2.34m
Annual income statement for BioRegenx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.404 | 0.199 | 0.042 | 3.41 | 2.34 |
| Cost of Revenue | |||||
| Gross Profit | 0.318 | 0.087 | 0.032 | 2.31 | 1.66 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.678 | 0.364 | 0.12 | 6.82 | 25.1 |
| Operating Profit | -0.274 | -0.165 | -0.078 | -3.41 | -22.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.274 | -0.097 | -0.078 | -3.6 | -23.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.274 | -0.097 | -0.078 | -3.6 | -23.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.274 | -0.097 | -0.078 | -3.6 | -23.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.274 | -0.097 | -0.078 | -3.6 | -23.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.001 | -0 | -0 | -0.006 | -0.007 |